Jacobs Levy Equity Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Jacobs Levy Equity Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$433K	Buy	+109,841	New	+$399K	﹤0.01%	844

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Jacobs Levy Equity Management's ELDN Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 109,841 shares worth $433K. The stake represents ﹤0.01% of the portfolio and ranks #844 among its holdings.

160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Jacobs Levy Equity Management held 109,841 shares of Eledon Pharmaceuticals worth $433K as of Q2 2026.
Eledon Pharmaceuticals was a new Jacobs Levy Equity Management position in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #844 holding.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.